SPRY

ARS Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ars-pharma.com
Employees(FY) 24
ISIN US82835W1080

Performance

-0.78%

-16.27%

+4.48%

+58.55%

+155.47%

YTD

+195.98%

Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.

Advanced Technical Analysis

Technical Analysis of SPRY 2024-11-22

The stock indicators reflect a predominantly neutral sentiment, with the Moving Average Score at 36 indicating bearish pressure, while the Oscillators Score at 46 and the overall Technical Score at 41 suggest a lack of strong momentum in either direction. This combination implies a cautious market outlook, with potential for volatility as trader...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SPRY

Stock Rank

Recent News & Updates

2024-11-15 06:50
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term(Simply Wall St.)
2024-11-14 03:18
ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing(MT Newswires)
2024-11-14 02:08
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...(GuruFocus.com)
2024-11-13 07:40
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates(Zacks)
2024-11-13 06:58
ARS Pharmaceuticals' Q3 Net Loss Widens(MT Newswires)
2024-11-13 06:30
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-11-12 17:30
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-11-12 07:06
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy(TipRanks)
2024-11-11 16:02
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray(Investor's Business Daily)
2024-11-11 11:01
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m(Pharmaceutical Technology)
2024-11-11 07:52
ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada(MT Newswires)
2024-11-11 07:00
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States(GlobeNewswire)
2024-11-10 18:41
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024(Yahoo Finance)
2024-11-10 18:00
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States(Globenewswire)
2024-11-09 04:30
ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)(Globenewswire)
2024-11-06 09:55
Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet(Zacks)
2024-11-06 08:00
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences(GlobeNewswire)
2024-11-05 19:00
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences(Globenewswire)
2024-10-24 12:36
VR Resources Confirms Gold in Porphyry Intrusion Cutting Nickel Sulfide Mineralization at Silverback Project in Ontario(MT Newswires)
2024-10-24 08:30
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting(GlobeNewswire)
2024-10-23 20:30
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting(Globenewswire)
2024-10-18 07:13
Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation(Simply Wall St.)
2024-10-14 09:55
Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade(Zacks)
2024-09-30 10:33
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?(Pharmaceutical Technology)
2024-09-23 11:59
ARS Pharmaceuticals Launches Neffy Nasal Spray in US(MT Newswires)
2024-09-23 08:00
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis(GlobeNewswire)
2024-09-22 20:00
ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis(Globenewswire)
2024-09-11 08:20
ARS Pharmaceuticals (SPRY): A Bull Case Theory(Insider Monkey)
2024-09-10 16:05
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference(GlobeNewswire)
2024-09-10 04:05
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.